Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.40 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8812961 | 1.00 | BCHE (0.40) | BCHEACHECACNA1FCACNA1DCACNA1S | |
| SCHEMBL7902197 | 0.85 | CCKBR (0.43) | BCHEACHECACNA1FCACNA1DCACNA1S | |
| SCHEMBL7902193 | 0.85 | CCKBR (0.43) | BCHEACHECACNA1FCACNA1DCACNA1S | |
| SCHEMBL7902106 | 0.80 | PYGL (0.38) | ALDH1A1HPGDKMT2A | |
| SCHEMBL21805219 | 0.79 | ALDH1A1 (0.48) | MEN1ALDH1A1HPGDKMT2ATACR1 | |
| SCHEMBL21805220 | 0.79 | ALDH1A1 (0.48) | MEN1ALDH1A1HPGDKMT2ATACR1 | |
| SCHEMBL8727972 | 0.78 | ALDH1A1 (0.43) | BCHEACHEALDH1A1POLB | |
| SCHEMBL8508563 | 0.76 | CCKBR (0.53) | CCKBRMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL8815308 | 0.76 | CCKBR (0.53) | CCKBRMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL8815104 | 0.75 | CCKBR (0.51) | CCKBRMEN1ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5958971-A | PRODRUGS OF NITROGEN MUSTARD, AN ANTICARCINOGENIC AND TUMOR AGENT; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT); BIOCHEMICAL CONJUGATION | ZENECA LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
| US-5714148-A | PRODRUGS WHICH ARE SUBSTRATES FOR CARBOXYPEPTIDASE G2 AND YIELD ACTIVE CYTOTOXIC DRUGS | ZENECA LIMITED (GB) | 1998-02-03 | — | — | US | disclosed |
| US-5660829-A | DEESTERIFYING COMPOUND TO FORM N-(4(N,N-BIS(2-CHLOROETHYL) AMINO)PHENOXYCARBONYL)-L-GLUTAMIC ACID-GAMMA-(3,5-DICARBOXY)ANILIDE | ZENECA LIMITED (GB) | 1997-08-26 | — | — | US | disclosed |
| US-5587161-A | TWO COMPONENT SYSTEM INCLUDING ANTIBODY OR ANTIGEN BINDING FRAGMENT CONJUGATED TO CARBOXYPEPTIDASE G ENZYME, COMPOUND CONVERTIBLE TO CYTOTOXIC DRUG UNDER INFLUENCE OF ENZYME | ZENECA LIMITED (GB) | 1996-12-24 | — | — | US | disclosed |
| EP-0651740-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1995-05-10 | — | — | EP | disclosed |
| US-5405990-A | For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents | ZENECA LIMITED (GB) | 1995-04-11 | — | — | US | disclosed |
| WO-1994002450-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |